LUPIN LIMITED

The U.S. general anesthesia drugs market is projected to grow from USD 1.98 Billion in 2024 to USD 2.56 Billion by 2033, driven by increasing surgical procedures, technological advancements, and regulatory updates. Key segments include propofol, intravenous drugs, knee and hip replacements, and hospitals, with ambulatory surgical centers expected to grow fastest. Major players include GE Healthcare, Pfizer, and Hospira Inc.

India contributes 8-10% of global API supply, with 1,500 pharma companies manufacturing and exporting APIs. Key players include Neuland Laboratories, Marksans Pharma, Dr Reddy's Laboratories, Cipla, and Lupin, each focusing on diverse therapeutic areas and expanding capabilities. Investors should evaluate financial health and adaptability due to regulatory challenges and market fluctuations.

Lupin and Takeda Pharmaceutical have signed a non-exclusive patent licence agreement for the commercialisation of Vonoprazan tablets in India, branded as Lupivon. The drug, a potassium-competitive acid blocker, will be available in 10mg and 20mg strengths and is approved for treating gastric ulcers, reflux esophagitis, duodenal ulcers, and as part of the Helicobacter pylori eradication regimen. This move aims to expand Lupin's gastroenterology portfolio in India, where acid peptic disorders are highly prevalent.

Indian pharma giants focus on quality over quantity, with complex product filings increasing. US generics sales show slight growth, and regulatory challenges ease. Nomura recommends Lupin for its upcoming launches and stable market shares, while noting setbacks. Sun Pharma's specialty segment growth slows, and Dr Reddy's faces market share declines. Cipla and Zydus Lifesciences show growth but face inspection and competition challenges.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

The pharmaceutical CDMO market is projected to grow from USD 173.2 billion in 2023 to USD 345.6 billion by 2033, driven by the rise in disorder prevalence. Asia Pacific led with a 43% share in 2023, while North America is expected to grow fastest. The API segment dominated in 2023, and the drug segment is forecasted to grow rapidly. Solid dosage forms and pain indications were the largest segments in 2023. Big pharmaceutical companies led the market, with increasing collaborations between CDMOs and pharmaceutical firms. Technological advancements, such as AI and IoT, present opportunities for market growth.

India, known as the 'Pharmacy of the World,' supplied vaccines and medicines globally during COVID-19, fulfilling 40% of U.S. generic drug demand and 25% of U.K. medicines. The $50 billion industry is projected to grow to $130 billion by 2030, driven by companies like Mankind Pharma, which acquired Bharat Serums and Vaccines for ₹13,600 crore. India faces regulatory challenges including complex drug approvals, IP issues, and API dependency, necessitating reforms like streamlined approval processes and boosting API self-sufficiency.

India, known as the 'Pharmacy of the World,' supplied vaccines and medicines globally during COVID-19, fulfilling 40% of U.S. generic drug demand and 25% of U.K. medicines. Mankind Pharma, a key player, expanded through strategic acquisitions. India's pharma industry faces regulatory challenges like complex approvals and API dependency, but reforms like streamlined processes and expanded PLI schemes could boost growth.

Indian pharma industry to reach $130 billion by 2030, potentially $450 billion by 2047. Glenmark, Lupin, and Zydus Lifesciences stocks surged up to 100% YTD, driven by U.S. market growth and FDA approvals.

Lupin's share price surged over 1% to a 52-week high after USFDA approval for its generic Mirabegron tablets for overactive bladder. Lupin and Zydus are the only companies with approval for both 25 mg and 50 mg strengths, enjoying 6 months exclusivity. Lupin also launched doxorubicin hydrochloride liposome injection in the US.